Latest news with #MetropolisHealthcareLtd
News18
a day ago
- Health
- News18
Why Regular Kidney Cancer Screening After 40 Is a Must
Last Updated: In a world where preventive health is gaining increasing importance, incorporating regular kidney check-ups alongside heart and liver assessments can offer holistic protection Kidney cancer, often dubbed the 'silent killer" of the urogenital tract, is steadily becoming a significant concern among individuals over the age of 40. With a high mortality rate and subtle early symptoms, this disease often goes undetected until it has progressed to an advanced stage. Experts now emphasize that regular screening post-40 can be a lifesaving intervention—especially for high-risk groups. A Growing Concern After 40 According to Dr Kavitha Vijayakumar, AVP & Lab Operations, Metropolis Healthcare Ltd (Tamil Nadu, Andhra Pradesh & Telangana), 'Kidney cancer most commonly occurs after 40 years of age, with a higher frequency in men compared to women. The risk is compounded by lifestyle factors like smoking, alcohol consumption, and hypertension." What makes kidney cancer particularly dangerous is its ability to remain asymptomatic. 'Sixty percent of patients with kidney cancer are indeed asymptomatic, which explains why early diagnosis is so rare. A quarter of them are already in the metastatic stage when diagnosed," she adds. Symptoms, when they do occur, are often vague such as easy fatigue or low back pain which can be easily misattributed to other common conditions. Why Screening Is Crucial 'While cardiac screenings and cholesterol checks have become commonplace after 40, kidney cancer screening is often overlooked despite its severity," notes Dr. Kavitha. She recommends a simple ultrasound, which can be highly sensitive in detecting kidney tumors, especially depending on the size and location of the lesion. These non-invasive screenings can help flag abnormalities before symptoms set in, offering a critical window for early intervention. Dr. Samir Khanna, Director, Urology, CK Birla Hospital, Delhi, echoes these concerns and provides a broader view of the evolving landscape. 'Kidney cancer is most frequently diagnosed between the ages of 50 and 70, but there's a noticeable rise in incidence starting as early as 40. Age is a well-established risk factor—along with smoking, hypertension, obesity, and prolonged exposure to toxins," he explains. Certain populations, especially long-term dialysis patients and those with a family history of kidney cancer or genetic disorders like Von Hippel-Lindau (VHL) syndrome, are particularly vulnerable. 'Fortunately," Dr. Khanna adds, 'screening doesn't need to be complicated. Non-invasive tools like routine urine tests and ultrasounds can help detect tumors incidentally in their early stages—often when the cancer is still manageable through minimally invasive treatments like partial nephrectomy or ablation." Advanced Tools & Technologies In recent years, there's been a significant shift toward innovative screening methods. 'Emerging technologies like liquid biopsies and circulating tumor DNA tests are showing promise in detecting tumors at a molecular level," says Dr. Khanna. 'Artificial intelligence is also being integrated into imaging to better differentiate between benign and malignant kidney masses." These advancements could soon revolutionize early detection, making screening even more precise and accessible. Both experts stress that kidney cancer screening after 40 should not be a luxury—it's a preventive essential, particularly for those with risk factors. As Dr. Kavitha rightly points out, 'Detecting kidney cancer early can mean the difference between a simple outpatient treatment and complex, life-altering surgery." In a world where preventive health is gaining increasing importance, incorporating regular kidney check-ups alongside heart and liver assessments can offer holistic protection. If you're over 40, especially with a personal or family history of the disease, speak to your healthcare provider about getting screened.
Business Standard
14-05-2025
- Business
- Business Standard
Kaveri Seed Company Ltd leads losers in 'A' group
Syrma SGS Technology Ltd, Metropolis Healthcare Ltd, BASF India Ltd and REC Ltd are among the other losers in the BSE's 'A' group today, 14 May 2025. Syrma SGS Technology Ltd, Metropolis Healthcare Ltd, BASF India Ltd and REC Ltd are among the other losers in the BSE's 'A' group today, 14 May 2025. Kaveri Seed Company Ltd tumbled 7.18% to Rs 1375 at 14:47 stock was the biggest loser in the BSE's 'A' the BSE, 14289 shares were traded on the counter so far as against the average daily volumes of 18893 shares in the past one month. Syrma SGS Technology Ltd lost 6.62% to Rs 527.65. The stock was the second biggest loser in 'A' the BSE, 3.66 lakh shares were traded on the counter so far as against the average daily volumes of 1.01 lakh shares in the past one month. Metropolis Healthcare Ltd crashed 4.93% to Rs 1617.95. The stock was the third biggest loser in 'A' the BSE, 8679 shares were traded on the counter so far as against the average daily volumes of 1860 shares in the past one month. BASF India Ltd corrected 4.32% to Rs 4371. The stock was the fourth biggest loser in 'A' the BSE, 2818 shares were traded on the counter so far as against the average daily volumes of 1316 shares in the past one month. REC Ltd fell 3.31% to Rs 388.4. The stock was the fifth biggest loser in 'A' the BSE, 8.41 lakh shares were traded on the counter so far as against the average daily volumes of 3.43 lakh shares in the past one month.
